Evidence map›Paper›PMID 30289812›Full record

ArticleAIDS (London, England)2018

Predicting diabetes risk among HIV-positive and HIV-negative women.

Karla I Galaviz, Michael F Schneider, Phyllis C Tien, C Christina Mehta, Ighovwerha Ofotokun, Jonathan Colasanti, Vincent C Marconi, Kartika Palar, Gina Wingood, Adaora A Adimora and 8 more

Abstract readMulticenter Study
In one paragraph

Article in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Risk Prediction in People Living With Human Immunodeficiency Virus: Are We Hitting the Target?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Karla I GalavizHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Michael F SchneiderDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Phyllis C TienDivision of Infectious Diseases, Department of Medicine, University of California-San Francisco.
C Christina MehtaDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University.
Ighovwerha OfotokunDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Jonathan ColasantiHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Vincent C MarconiHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Kartika PalarDivision of Infectious Diseases, Department of Medicine, University of California-San Francisco.
Gina WingoodDepartment of Sociomedical Sciences, Lerner Center for Public Health Promotion, Mailman School of Public Health at Columbia University, New York, New York.
Adaora A AdimoraDivision of Infectious Disease, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Maria AlcaideDivision of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida.
Mardge H CohenDepartment of Medicine, Stroger Hospital and Rush University, Chicago, Illinois.
Deborah GustafsonDepartment of Neurology (D.G.), SUNY-Downstate Medical Center, Brooklyn, New York.
Roksana KarimDepartment of Preventive Medicine, University of Southern California, Los Angeles, California.
Deborah Konkle-ParkerUniversity of Mississippi Medical Center, Jackson, Mississippi.
Daniel MerensteinDepartment of Family Medicine, Georgetown University Medical Center, Washington, District of Columbia.
Anjali SharmaDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Mohammed K AliHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
UNC MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146194 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Bradley Drummond, Michelle Floris-Moore · 2019 to 2026
$23.2M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000454NHLBI NIH HHS U01 HL146194NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS R38 AI140299NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01 AI103390NIAID NIH HHS U01 AI103397NIAID NIH HHS U01 AI103401NIAID NIH HHS U01 AI103408NIA NIH HHS U54 AG062334NICHD NIH HHS U01 HD032632NIDDK NIH HHS P30 DK111024
6 · The paper itself

Abstract

objectiveTo assess the performance of an adapted American Diabetes Association (ADA) risk score and the concise Finnish Diabetes Risk Score (FINRISC) for predicting type 2 diabetes development in women with and at risk of HIV infection.

designLongitudinal analysis of the Women's Interagency HIV Study.

methodsThe women's Interagency HIV Study is an ongoing prospective cohort study of women with and at risk for HIV infection. Women without prevalent diabetes and 3-year data on fasting blood glucose, hemoglobin A1c, self-reported diabetes medication use, and self-reported diabetes were included. ADA and FINRISC scores were computed at baseline and their ability to predict diabetes development within 3 years was assessed [sensitivity, specificity and area under the receiver operating characteristics (AUROC) curve].

resultsA total of 1111 HIV-positive (median age 41, 60% African American) and 454 HIV-negative women (median age 38, 63% African-American) were included. ADA sensitivity did not differ between HIV-positive (77%) and HIV-negative women (81%), while specificity was better in HIV-negative women (42 vs. 49%, P = 0.006). Overall ADA discrimination was suboptimal in both HIV-positive [AUROC = 0.64 (95% CI: 0.58, 0.70)] and HIV-negative women [AUROC = 0.67 (95% CI: 0.57, 0.77)]. FINRISC sensitivity and specificity did not differ between HIV-positive (72 and 49%, respectively) and HIV-negative women (86 and 52%, respectively). Overall FINRISC discrimination was suboptimal in HIV-positive [AUROC = 0.68 (95% CI: 0.62, 0.75)] and HIV-negative women [AUROC = 0.78 (95% CI: 0.66, 0.90)].

conclusionModel performance was suboptimal in women with and at risk of HIV, while greater misclassification was generally observed among HIV-positive women. HIV-specific risk factors known to contribute to diabetes risk should be explored in these models.

Indexed as

Decision Support TechniquesAdultAgedAged, 80 and overDiabetes Mellitus, Type 2FemaleHIV InfectionsHumansLongitudinal StudiesMiddle AgedProspective StudiesRisk AssessmentRisk FactorsROC Curve

Identifiers

PMID30289812
PMCPMC6673643

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.